침습성 폐 아스페르길루스증의 역학과 임상상: 전국 다기관 연구
Epidemiology and Clinical outcomes of Invasive Pulmonary Aspergillosis: A Nationwide Multicenter Study in Korea
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background: Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunocompromised patients. However, few data on clinical characteristics and outcomes of IPA in Korea have been reported. We conducted a nationwide multicenter study in Korea for evaluation of the epidemiology and clinical outcomes of invasive pulmonary aspergillosis. Materials and Methods: A retrospective cohort study was conducted in 10hospitals in Korea. We reviewed all adult patients who met the revised EORTC/MSG definitions between 2008 and 2010. Results: A total of 334 cases, which included proven (26, 8%), probable (159, 48%),or possible (149, 44%) IPA, were identified. Patients with proven or probable IPA were evaluated, and, of these 185 IPA patients, 105 (57%) had neutropenia, 30 (16%)underwent hematopoietic stem cell transplantation, 25 (14%) underwent solid organ transplantation, and 32 (17%) without neutropenia and transplantation received immunosuppressive agents or corticosteroid. Aspergillus spp. were isolated from 42 patients (23%), and positive fungal culture rates from sterile fluid, sputum, and bronchoalveolar lavage fluid (BAL) were 67% (6/9), 21% (32/150), and 20% (9/44),respectively. Results of assays for sensitivity of serum and BAL galactomannan were 84% (155/184) and 89% (25/28), respectively. Amphotericin-B deoxycholate and itraconazole were most commonly administered as a primary therapy in 107 (58%)and 34 (19%) patients, respectively. Of 133 patients (73%) who received salvage therapy after primary antifungal therapy for a median period of six days (IQR 3-12), 82(62%) patients were treated with voriconazole. Of 185 patients, 82 (44%) died within three months after diagnosis of IPA. CT findings, including small airway lesions and micronodules, ground glass opacities, and pleural effusion and persistent positive galactomannan status showed an independent association with worse outcome, while proven diagnosis of IPA showed an independent association with better outcome. Conclusions: Microbiologic confirmation of IPA was low in Korea; therefore, many Korean physicians were dependent on the galactomannan assay for microbiologic diagnosis. Primary therapy with Amphotericin-B deoxycholate followed by salvage therapy with voriconazole was the most common antifungal strategy for treatment of patients with IPA in Korea. Overall mortality and IPA-related mortality were comparable with data from Western clinical trials.
Abstract
Background: Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunocompromised patients. However, few data on clinical characteristics and outcomes of IPA in Korea have been reported. We conducted a nationwide multicenter study in Korea for evaluation of the epidemiology and clinical outcomes of invasive pulmonary aspergillosis. Materials and Methods: A retrospective cohort study was conducted in 10hospitals in Korea. We reviewed all adult patients who met the revised EORTC/MSG definitions between 2008 and 2010. Results: A total of 334 cases, which included proven (26, 8%), probable (159, 48%),or possible (149, 44%) IPA, were identified. Patients with proven or probable IPA were evaluated, and, of these 185 IPA patients, 105 (57%) had neutropenia, 30 (16%)underwent hematopoietic stem cell transplantation, 25 (14%) underwent solid organ transplantation, and 32 (17%) without neutropenia and transplantation received immunosuppressive agents or corticosteroid. Aspergillus spp. were isolated from 42 patients (23%), and positive fungal culture rates from sterile fluid, sputum, and bronchoalveolar lavage fluid (BAL) were 67% (6/9), 21% (32/150), and 20% (9/44),respectively. Results of assays for sensitivity of serum and BAL galactomannan were 84% (155/184) and 89% (25/28), respectively. Amphotericin-B deoxycholate and itraconazole were most commonly administered as a primary therapy in 107 (58%)and 34 (19%) patients, respectively. Of 133 patients (73%) who received salvage therapy after primary antifungal therapy for a median period of six days (IQR 3-12), 82(62%) patients were treated with voriconazole. Of 185 patients, 82 (44%) died within three months after diagnosis of IPA. CT findings, including small airway lesions and micronodules, ground glass opacities, and pleural effusion and persistent positive galactomannan status showed an independent association with worse outcome, while proven diagnosis of IPA showed an independent association with better outcome. Conclusions: Microbiologic confirmation of IPA was low in Korea; therefore, many Korean physicians were dependent on the galactomannan assay for microbiologic diagnosis. Primary therapy with Amphotericin-B deoxycholate followed by salvage therapy with voriconazole was the most common antifungal strategy for treatment of patients with IPA in Korea. Overall mortality and IPA-related mortality were comparable with data from Western clinical trials.
참고문헌 (18)
- De Pauw B., "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Kontoyiannis DP., "Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006 : overview of the Transplant-Associated Infection Surveillance Network(TRANSNET)Database", Clin Infect Dis, 50, pp.1091~1100 (2010)
- Pappas PG., "Invasive fungal infections among organ transplant recipients : results of the Transplant-Associated Infection Surveillance Network(TRANSNET)", Clin Infect Dis, 50, pp.1101~1111 (2010)
- 강철인, "침습성 아스페르길루스증의 발생 양상과 치료결과", Infection and Chemotherapy, 34(3), pp.160~166 (2002), 대한감염학회
- Jong Man Kim, "Aspergillosis in Liver Transplant Recipients: A Single Center Experience", 대한외과학회지, 79(4), pp.267~274 (2010), 대한외과학회
- 유진홍, "혈액질환 환자에서 조혈모세포 이식과화학요법 후의 침습성 진균감염의 분석", Infection and Chemotherapy, 36(1), pp.40~45 (2004), 대한감염학회
- 박성연, "Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients", TRANSPLANT INFECTIOUS DISEASE, 12, pp.309~315, Wiley
- Hope WW., "Laboratory diagnosis of invasive apsergillosis", Lancet Infect Dis, 5, pp.609~622 (2005)
- 김성한, "Fatal pandemic influenza A", H1N1 infection complicated by probable invasive pulmonary aspergillosis, 2012, pp.55(2), 189~192[DOI]
- 박성연, "Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value", JOURNAL OF INFECTION, 63(6), pp.447~456 (2011), W B SAUNDERS CO LTD
- Pfeiffer CD., "Diagnosis of invasive aspergillosis using galactomannan assay : a meta-analysis", Clin Infect Dis, 42, pp.1417~1427 (2006)
- 박성연, "Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis", JOURNAL OF INFECTION, 61(6), pp.492~498, W B SAUNDERS CO LTD
- Hachem RY., "Utility of galactomannan enzyme immunoassay and(1, 3)beta-D-glucan in diagnosis of invasive fungal infections : low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients", J Clin Microbiol, 47, pp.129~133 (2009)
- Walsh TJ., "Treatment of aspergillosis : clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.327~360 (2008)
- Herbrecht R., "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347, pp.408~415 (2002)
- Woods G., "Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis : a study of 56 patients with hematologic cancer", Cancer, 110, pp.830~834 (2007)
- Maertens J., "Galactomannan serves as surrogate endpoint for outcome of pulmonary aspergillosis in neutropenic hematologic patients", Cancer, 115, pp.355~362 (2009)
- Mennink-Kersten MA., "Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis", Lancet Infect Dis, 4, pp.349~357 (2004)